Stockreport

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

PDS Biotechnology Corporation  (PDSB) 
Last pds biotechnology corporation earnings: 11/7 06:00 am Check Earnings Report
PDF Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cel [Read more]